PlainPharmaWatch

CMS Open Payments · Program Year 2024

IBSA Institut Biochimique SA

IBSA Institut Biochimique SA reported $11,408,255.66 across General Payments, Research, and Ownership to 17 physicians and teaching hospitals across 371 transactions.

See the rankings → How this is sourced
$11.4M Top 10% payer
All-tracks total
371 Above-median volume
Transactions
17 Below-median reach
Recipients
−$34.6K
General Payments vs PY2023

IBSA Institut Biochimique SA reported $11,408,255.66 across all CMS Open Payments tracks (General + Research + Ownership) to 17 physicians and teaching hospitals in Program Year 2024 - ranking #154 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $50,002.72, averaging $671.1K per recipient.

How IBSA Institut Biochimique SA's $11.4M all-tracks total breaks down

IBSA Institut Biochimique SA's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

47/100

Total payments

A

100/100

Transaction volume

F

13/100

Physician reach

F

10/100

Payment type diversity

D

63/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer ibsa-institut-biochimique-sa IBSA Institut Biochimique SA

$11.4M · #154/1,925 · 0.1% industry · PY2024

  • TOT $11.4M
  • RANK #154
  • SHARE 0.1%
  • TXN 371
  • RCP 17
  • CAT 5
  • GEN $50.0K
  • ΔGEN −$34.6K
  • TOP1 40.0%
  • PY 2024

Volume peers

Nearest volume peer: Ocular Therapeutix, Inc. ($11.4M)

Iovance Biotherapeutics, Inc.$11.5MOcular Therapeutix, Inc.$11.4MIBSA Institut Biochimique SA…$11.4MTris Pharma Inc$11.4MAbiomed$11.3M
All-tracks payment totals near IBSA Institut Biochimique SA (CMS Open Payments PY2024)

IBSA Institut Biochimique SA sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

IBSA Institut Biochimique SA's CMS-reported General Payments decreased by $34.6K (−40.9%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: IBSA INSTITUT BIOCHIMIQUE SAPY2023: IBSA INSTITUT BIOCHIMIQUE SAPY2024: IBSA Institut Biochimique SA. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$84.7KPY2024$50.0K
PY2023
$84,652.41
PY2024
$50,002.72

What the Data Shows for IBSA Institut Biochimique SA

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For IBSA Institut Biochimique SA, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $41.2K, accounting for 82.3% of this company's General Payments and 10 transactions.

General Payment Breakdown by Type

IBSA Institut Biochimique SA made 5 types of general payments. "Consulting Fee" is the largest category at $41.2K, 82.3% of General Payments.

IBSA Institut Biochimique SA reports 5 general-payment categories - the top three are Consulting Fee (82.3%), Compensation for Services Other Than Consulting (8.0%), and Travel and Lodging (7.0%). The remaining 2 categories make up 2.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How IBSA Institut Biochimique SA divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$41.2K2. Compensation for Services…$4.0K3. Travel and Lodging$3.5K4. Grant$1.3K5. Food and Beverage$32.00
Payment Type Amount Transactions
Consulting Fee $41.2K 10
Compensation for Services Other Than Consulting $4.0K 2
Travel and Lodging $3.5K 3
Grant $1.3K 1
Food and Beverage $32.00 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $44,673.55 (89.3%) of $50,002.72 in this company's General Payments records across 8 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for IBSA Institut Biochimique SA

The five named recipients with the highest reported General Payments from this company

Zbigniew Paul Lorenc$20.0KHema a. Sundaram$13.0KJames Toner$4.9KMichael Howard Gold$4.0KValerie Lynn Baker$2.8K
  1. 1

    Zbigniew Paul Lorenc

    $20,000.00 across 2 reported transactions

  2. 2

    Hema a. Sundaram

    $13,000.00 across 3 reported transactions

  3. 3

    James Toner

    $4,857.80 across 2 reported transactions

  4. 4

    Michael Howard Gold

    $4,000.00 across 1 reported transactions

  5. 5

    Valerie Lynn Baker

    $2,815.75 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

IBSA Institut Biochimique SA ranks #154 of 1,925 by total payments (top 8% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #644 of 1,838 by HHI (top 35% most concentrated), a wider distribution than most similarly sized payers.

01.83.75.57.32494.32509.42524.52539.62554.8Total payments ($M)Concentration (HHI, 0-10,000)
IBSA Institut Biochimique SA (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as IBSA Institut Biochimique SA's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about IBSA Institut Biochimique SA.

Avirmax Biopharma, Inc

HHI 2519

Oxford Performance Materials, Inc.

HHI 2520

Ignite Orthomotion LLC

HHI 2504

NuMED for Children, LLC

HHI 2500

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with IBSA Institut Biochimique SA.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

IBSA Institut Biochimique SA ranks #154 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download IBSA Institut Biochimique SA's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.